Vertaile menetelmiä
Tarkastele valitsemiasi menetelmiä rinnakkain; eroavat rivit korostetaan.
| Kiinteä dispersio× | Caco-2-soluuttimääritys× | |
|---|---|---|
| Tieteenala | Farmakologia | Farmakologia |
| Menetelmäperhe | Process / pipeline | Process / pipeline |
| Syntyvuosi≠ | 1971 | 1989 |
| Kehittäjä≠ | William Chiou and Solomon Riegelman | Ingrid Hidalgo |
| Tyyppi≠ | solubility enhancement | absorption screening |
| Alkuperäislähde≠ | Chiou, W. L., Riegelman, S. (1971). Pharmaceutical applications of solid dispersions. Journal of Pharmaceutical Sciences, 60(9), 1281-1302. link ↗ | Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749. DOI ↗ |
| Rinnakkaisnimet | solid solution, amorphous dispersion, polymer-based formulation | Caco-2 assay, intestinal permeability, ADME screening |
| Liittyvät | 3 | 3 |
| Tiivistelmä≠ | Solid dispersion is a formulation technique where a poorly soluble drug is molecularly dispersed in a hydrophilic polymer matrix, improving aqueous solubility and bioavailability. Introduced by Chiou and Riegelman in 1971, solid dispersions remain a key strategy for overcoming solubility-limited absorption. | The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport. |
| ScholarGateAineisto ↗ |
|
|